May 3, 2018 / 10:38 AM / 2 months ago

Regeneron's first quarter profit soars 92 percent

May 3 (Reuters) - Regeneron Pharmaceuticals Inc on Thursday posted a 92 percent rise in quarterly profit, as demand for its flagship eye treatment Eylea and eczema drug Dupixent increased.

Net income rose to $478 million, or $4.16 per share, in the quarter ended March. 31, from $248.9 million, or $2.16 per share, a year ago.

Total revenue rose to $1.51 billion from $1.32 billion. (Reporting by Tamara Mathias in Bengaluru; Editing by Shailesh Kuber)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below